EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barandon, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barandon, L.
Related Collections
Right arrow Congestive Heart Failure
Right arrow Transplantation - heart
Right arrowRelated Article

Eur J Cardiothorac Surg 2004;25:350-351
© 2004 Elsevier Science NL

Editorial comment

Cellular cardiomyoplasty: ‘inject is easy, demonstrate is complicated’

Laurent Barandon*

Pr Deville, Department of Cardiovascular Surgery, Haut-Lévêque Hospital, 33600 Pessac, France

* Tel.: +33-557-65-6565; fax: +33-556-36-8979
e-mail: lesbarandon@wanadoo.fr

The first 20% of the full text of this article appears below.

In the last decade, improvements in cell biology, cell selection and cell culture have led to the development and refinement of a new strategy to treat ischemic and post-infarction heart diseases [1]. The goal for cell therapy or cellular cardiomyoplasty is to repopulate the scar, to develop new contractile activity, and eventually to improve scar perfusion. Cell therapy offers cardiac surgeons new fields of experimental and clinical research for treating infarcted and ischemic cardiac tissues [2]. Two of the most widely used cell types in this new strategy are skeletal muscle-derived progenitors or myoblasts and mononuclear bone marrow-derived cells (BM-MDC). These cells are autologous and easily expandable in vitro. The relative limitation of myoblasts is maintained in muscle phenotype [2]. However, they are well integrated in the scar and are able to improve cardiac function. In contrast, BM-MDC are potentially interesting for their capacity to transdifferentiate into cardiomyocytes and endothelial cells. BM-MDC are . . . [Full Text of this Article]


Related Article

Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease
Mustafa Ozbaran, Serdar B. Omay, Sanem Nalbantgil, Hakan Kultursay, Kamil Kumanlioglu, Deniz Nart, and Erman Pektok
Eur. J. Cardiothorac. Surg. 2004 25: 342-350. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.